Halozyme Therapeutics, Inc. (HALO) Institutional Ownership & Insider Trading

667 institutions reported holding Halozyme Therapeutics, Inc. shares in 13F filings for the quarter ended 2026-06-30, according to EquiReason's reading of their SEC filings. 120 insider trades on Form 4 since 2025-10-01.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

HALOHalozyme Therapeutics, Inc.Follow HALO — free

Biotechnology · Healthcare

—

Price chart with a free account

Market cap: 14.3B
P/E TTM: 36.6
Dividend yield: —
52-week: —
Next earnings: 5 Nov, in 12 days

Institutions · all 13F filers

quarter to 30 Jun 2026 · filers in both quarters

667 institutions held —% of the shares. Across filers that reported both quarters, shares held changed +1.8%.

Largest moves, shares (millions)

Institutional flow by quarter

net shares added or trimmed, millions · filers in both quarters

Quarter	Holders	Shares held, M	Change	Increased	New	Decreased	Closed
Jun 26	667	124	+1.8%	244	85	183	55
Mar 26	630	120	-1.1%	203	75	194	53
Dec 25	602	124	+0.7%	190	58	198	70
Sep 25	588	120	+3.8%	165	96	210	36
Jun 25	541	116	-3.9%	165	74	192	72
Mar 25	534	120	-0.4%	194	78	139	36
Dec 24	498	122	-4.8%	151	56	148	73
Sep 24	498	124	+1.9%	160	76	149	33

Halozyme Therapeutics, Inc. — questions

Who owns Halozyme Therapeutics, Inc. stock?: 667 institutions reported Halozyme Therapeutics, Inc. shares in 13F filings for the quarter ended 2026-06-30. The largest: BlackRock, Inc. (11.7%), VANGUARD CAPITAL MANAGEMENT LLC (4.7%), VANGUARD PORTFOLIO MANAGEMENT LLC (4.7%).
Are Halozyme Therapeutics, Inc. insiders buying or selling?: 120 insider trades on Form 4 since 2025-10-01; the full list, with dates, people and plan status, is on this page.

Every figure on this page comes from Halozyme Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.